Ani Pharmaceuticals (ANIP) Cash & Equivalents (2010 - 2026)

Ani Pharmaceuticals has disclosed Cash & Equivalents across 17 years of filings, most recently posting $311.2 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $311.2 million, up 107.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $311.2 million (up 107.72% YoY), and the FY2025 annual result was $285.6 million, up 97.14% from the prior year.
• Cash & Equivalents came in at $311.2 million for Q1 2026 at Ani Pharmaceuticals, up from $285.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $311.2 million in Q1 2026 to a low of $48.2 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $161.7 million (2023), against an average of $169.1 million.
• Across the five-year window, Cash & Equivalents tumbled 51.92% in 2022 and jumped 358.49% in 2023, its largest moves.
• Ani Pharmaceuticals' Cash & Equivalents stood at $48.2 million in 2022, then soared by 358.49% to $221.1 million in 2023, then slumped by 34.49% to $144.9 million in 2024, then soared by 97.14% to $285.6 million in 2025, then advanced by 8.96% to $311.2 million in 2026.
• The last three Cash & Equivalents figures came in at $311.2 million (Q1 2026), $285.6 million (Q4 2025), and $262.6 million (Q3 2025), per Business Quant data.